Menu
No results found.
688426
Jiangsu CoWin Biotech Co., Ltd. – SHA
Weekly Share Price & Valuation Overview
Market Overview
Open
24.2000
Close
24.3500
High
25.2000
Low
24.1000
Trend
0.46616
Jiangsu CoWin Biotech Co., Ltd.
China
• SHA - Shanghai Stock Exchange
• 688426
• Currency: CNY
Jiangsu CoWin Biotech Co., Ltd. engages in the research and development, production, and sale of biological products in China. The company provides molecular diagnostic raw material enzymes, nucleic acid collection and protection agents, nucleic acid extraction and purification kits, molecular diagnostic testing reagents, etc. It also offers medical device products, nucleic acid collection and protection, PCR, RT-PCR, and qPCR products, molecular diagnosis, isothermal amplification, nucleic acid mass spectrometry, next generation sequencing, nucleic acid extraction and purification, marker clone transfection, antibody, protein detection products, and scientific research instruments. The company was founded in 2010 and is headquartered in Taizhou, China.
Key strengths
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Revenue growth ≥10% indicates solid top-line momentum.
- Earnings growth ≥10% supports improving profitability trajectory.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
Potential weaknesses
- Negative free cash flow — operations may rely on external financing.
Scale & Structure
Core size and share structure. TTM values unless noted. “Estimated” where reconciled from per-share × shares.
- Market Cap Total equity value of the company (share price × shares outstanding).
- CNY 2.68B
- Enterprise Value Operating value: market cap + total debt − cash.
- CNY 2.02B
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- CNY 140.08M
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- CNY 68.21M
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- CNY -152.76M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- CNY 1.26
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- -1.36
- Shares Outstanding
- 112.49M
- Float Shares
- 35.28M
- Implied Shares Outstanding
- 112.49M
Profitability & Efficiency
TTM basis. “Reconciled” = numerator ÷ TTM revenue. Margins reflect latest TTM calculations.
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
-70.55%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
-109.05%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
48.70%
- Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
-
-1.08%
- ROA Return on assets: net income ÷ total assets.
-
-6.75%
- ROE Return on equity: net income ÷ shareholder equity.
-
-9.95%
Growth
Growth rates are YoY unless labeled QoQ.
- Revenue Growth Strong Year-over-year revenue growth.
-
49.30%
- Earnings Growth (YoY) Strong Year-over-year earnings growth.
-
17.69%
Liquidity & Solvency
Balance-sheet health. Debt metrics shown as latest ratios; D/E is a ratio (not %).
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 9.67
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 1.98
- Total Cash Cash and equivalents.
- CNY 650.10M
- Total Debt Short + long-term interest-bearing debt.
- CNY 28.85M
- Net Debt Net Cash Total debt − cash (negative = net cash).
- CNY -621.25M
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- -0.19
Cash Flow
Shown only when internally consistent; margins are TTM.
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- CNY -102.73M
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- CNY -103.80M
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
-73.34%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
-74.10%
- Cash Conversion (OpCF/EBITDA)
- 0.67
Sharemaestro House View
Confidence: 1
Sharemaestro internal conviction (0–3, higher is better).
Risk: 1
Sharemaestro internal risk profile (0–3, higher is safer).
Operational: 1
Operational quality/consistency (0–3, higher is better).
Composite Score: 2
Overall internal composite (0–3, higher is better).
Suggested Allocation: 3.33%
Indicative portfolio weighting suggestion based on house view.
Structural Insights
(experimental)
Ownership & Liquidity
Free Float
Proportion of shares available for public trading.
31.4%
Insiders
Shares held by company insiders (officers, directors).
67.8%
Institutions
Shares held by institutions (funds, pensions).
8.5%
Capital Structure
Potential Dilution
Increase in share count if options/convertibles exercise.
None detected
Net Debt
Total debt − cash (negative = net cash).
CNY -621.25M
-443.5% of revenue
Net debt relative to revenue — debt load vs business scale.
Resilience Score
0–100 composite of liquidity, leverage and cash conversion; higher is better. If inputs are unavailable, we estimate using proxies (Net debt vs revenue, Cash-to-Debt). It is a guide, not a rating.
82
Methodology Notes
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
As of: 2025-08-18 10:15
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.
AI generated insights not available yet. Sign in to generate the snapshot.